Long-lasting Responses to Immunomodulatory Drugs (IMIDs) in Combination with Dexamethasone in Multiple Myeloma; Identification of Exceptional Responders at any Treatment Line
Journal Title: Haematology International Journal - Year 2017, Vol 1, Issue 2
Abstract
1.1. Background: There is a growing interest in the study of patients that achieve exceptionally long-lasting remissions although suffering from incurable neoplastic disorders. This is the case for multiple myeloma (MM), the treatment of which has greatly improved with the emergence of new, biology-driven modalities that prolonged survival. The identification of “exceptional responders” to basic treatment such as immunoregulatory drugs (IMIDs) and dexamethasone could eventually reveal a small proportion of patients potentially curable with more drugs combinations. 1.2. Aims: To investigate MM exceptional responders to IMiDs. 1.3. Objectives: To identify exceptional responders among all patients with symptomatic MM treated either at diagnosis or in relapse with an IMID (thalidomide, lenalidomide, pomalidomide) in combination with dexamethasone and to study their clinical characteristics and survival. 1.4. Materials and Methods: A cohort of 164 patients was studied. “Exceptional responders” were defined as patients that remained in remission for at least 72 months after 1st line treatment, 60 months after 2nd line, 42 months after 3rd to 6th line and for at least 30 months beyond 6th line. Statistical analysis was performed using the SPSS v.24.0 software. Survival was evaluated by the log rank test. 1.5. Results: Thirty-one (19%) exceptional responders were detected, of whom 11 (15%) out of 75 received thalidomide/dexamethasone (TD), 18 (14%) out of 132 lenalidomide/dexamethasone (LD) and 2 (25%) out of 8 pomalidomide dexamethasone (PD). The median number of treatment lines received prior to TD, LD and PD treatment was 2, 2 and 7 respectively. Exceptional responders’ survival from TD, LD and PD treatment to last follow-up or death was 85, 73 and 35 months while their overall survival was 95, 94,5 and 149 months respectively. Seventeen patients are alive and 4 disease-free. They did not exhibit specific clinical or biochemical profile beside the absence of hypercalcemia and extramedullary disease at treatment initiation. 1.6. Conclusion: We identified exceptional responders to IMIDs-based treatment, their further examination may enlighten on disease biologic aspects that could open the way to cure.
Authors and Affiliations
Marie-Christine Kyrtsonis
Keywords
Related Articles
- EP ID EP291039
- DOI -
- Views 135
- Downloads 0
Hemochromatosis Gene Mutation and Erythrocytosis
In a patient group presenting with either increased Hgb level or high RBC count HFE gene mutations occured in two-third of the patients. The explanation for this phenomenon is still missing. These patients had normal ery...
Multiple Myeloma in Cameroon: Clinico-Biological Characteristics of Patients; an Experience from Douala General Hospital
1.1. Background: Multiple myeloma is the most common haematological malignancy among blacks. There is paucity of data on this subject in Africa in general and Cameroon in Cameroon. This study aims at describing initial c...
Determining Concentrations of Factors Viii, IX and Fibrinogen in Fresh Frozen Plasma: An Alternative to Improve Treatment of Hemorrhagic Diseases in a Developing Country
Fresh frozen plasma (FFP) remains the only treatment of bleeding events in some developing countries. But access to this blood derived-product could be difficult. Determined the concentrations of coagulation factors VIII...
The Stellar, Astral Reproduction: Burkitt ‘S Lymphoma
An infrequent (≤1.2%), aggressive B lymphocyte non hodgkin’s lymphoma is designated as a Burkitt’s lymphoma, which may present as an extra-nodal tumefaction or as an acute leukaemia [1]. A well delineated clinico-patholo...
Platelet Hyperaggregation and Morphological Changes By Electron Microscopy in Simulated Dive
Dysbaric osteonecrosis and electroencephalogram (EEG) disturbances prompted the previous studies already submitted at Argentine Society of Haematology on the Scientific Meeting at 1982 and on the First Haemotherapy and I...